Comparative Pharmacology
Head-to-head clinical analysis: METROCREAM versus METROGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROCREAM versus METROGEL.
METROCREAM vs METROGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Topical, apply a thin film to affected area once or twice daily.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)